BELLUS Health to Present at the Bloom Burton & Co. Healthcare Investor Conference

Rhea-AI Summary

BELLUS Health (Nasdaq:BLU) announces that President and CEO Roberto Bellini will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 2:00 p.m. ET. BELLUS Health focuses on developing novel therapeutics for refractory chronic cough and hypersensitization-related disorders. Their lead candidate, BLU-5937, addresses refractory chronic cough, affecting around 9 million patients in the U.S., and chronic pruritus associated with atopic dermatitis. Currently, no specific therapy exists for these conditions, highlighting the need for innovative treatments.

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will present a corporate overview of the Company at the Bloom Burton & Co. Healthcare Investor Conference.

Presentation Details:

Event: Bloom Burton & Co. Healthcare Investor Conference
Date/Time: Tuesday, April 20, 2021 at 2:00 p.m. ET

A live webcast of the presentation may be accessed on the Events & Presentations page under the Investors & Media section of BELLUS Health's website at www.bellushealth.com. Following the event, an archived webcast will be available on the Company’s website.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders. The Company's product candidate, BLU-5937, is being developed for the treatment of refractory chronic cough and chronic pruritus associated with atopic dermatitis.

Refractory chronic cough is a cough lasting more than 8 weeks despite appropriate treatment for underlying condition(s). It is estimated that there are approximately 9 million patients in the United States suffering from refractory chronic cough. Refractory chronic cough is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for refractory chronic cough and current treatment options are limited.

Chronic pruritus associated with atopic dermatitis is an irritating sensation that leads to scratching and persists for longer than 6 weeks in atopic dermatitis patients. It is estimated that 5% of adults in the United States suffer from atopic dermatitis – almost all report symptoms of pruritus with over 50% of patients attributing chronic pruritus as their most burdensome symptom. Despite currently available treatments targeting atopic dermatitis, there continues to be a lack of options targeting the burden of pruritus in patients with atopic dermatitis.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210413005285/en/

FAQ

What is the date and time of BELLUS Health's presentation at the Bloom Burton & Co. Healthcare Investor Conference?

BELLUS Health's presentation will take place on April 20, 2021, at 2:00 p.m. ET.

Who will present at the Bloom Burton & Co. Healthcare Investor Conference for BELLUS Health?

Roberto Bellini, the President and CEO of BELLUS Health, will present at the conference.

What is the primary focus of BELLUS Health's drug development?

BELLUS Health is developing therapeutics for refractory chronic cough and other hypersensitization-related disorders.

How many people in the U.S. suffer from refractory chronic cough according to BELLUS Health?

Approximately 9 million patients in the U.S. suffer from refractory chronic cough.

What is the product candidate BLU-5937 designed to treat?

BLU-5937 is being developed for the treatment of refractory chronic cough and chronic pruritus associated with atopic dermatitis.

Where can I access the live webcast of BELLUS Health's presentation?

The live webcast can be accessed on the Events & Presentations page of BELLUS Health's website.